These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 23423222)
1. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST. Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222 [TBL] [Abstract][Full Text] [Related]
2. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448 [TBL] [Abstract][Full Text] [Related]
3. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors. Ahsan S; Ge Y; Tainsky MA Oncotarget; 2016 Aug; 7(35):57171-57185. PubMed ID: 27494873 [TBL] [Abstract][Full Text] [Related]
4. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690 [TBL] [Abstract][Full Text] [Related]
6. Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression. Su W; Sin M; Darrow A; Sherman LS Glia; 2003 Jun; 42(4):350-8. PubMed ID: 12730955 [TBL] [Abstract][Full Text] [Related]
7. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697 [TBL] [Abstract][Full Text] [Related]
8. Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS. Reuss DE; Mucha J; Hagenlocher C; Ehemann V; Kluwe L; Mautner V; von Deimling A PLoS One; 2013; 8(2):e57152. PubMed ID: 23437333 [TBL] [Abstract][Full Text] [Related]
9. The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors. Kraniak JM; Sun D; Mattingly RR; Reiners JJ; Tainsky MA Mol Cell Biochem; 2010 Nov; 344(1-2):267-76. PubMed ID: 20680410 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032 [TBL] [Abstract][Full Text] [Related]
11. Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling. Barkan B; Kloog Y; Ehrlich M Mol Cancer Ther; 2011 Aug; 10(8):1317-26. PubMed ID: 21632464 [TBL] [Abstract][Full Text] [Related]
12. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors. Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988 [TBL] [Abstract][Full Text] [Related]
13. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations. Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373 [No Abstract] [Full Text] [Related]
14. Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor. Park GH; Lee SJ; Lee CG; Kim J; Park E; Jeong SY Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948100 [TBL] [Abstract][Full Text] [Related]
15. The promise of signal transduction in genetically driven sarcomas of the nerve. Kim A; Pratilas CA Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862 [TBL] [Abstract][Full Text] [Related]
16. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. Shapira S; Barkan B; Friedman E; Kloog Y; Stein R Cell Death Differ; 2007 May; 14(5):895-906. PubMed ID: 17096025 [TBL] [Abstract][Full Text] [Related]
17. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors. Wang J; Pollard K; Calizo A; Pratilas CA Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698 [TBL] [Abstract][Full Text] [Related]
18. PACAP and VIP affect NF1 expression in rat malignant peripheral nerve sheath tumor (MPNST) cells. Giunta S; Castorina A; Adorno A; Mazzone V; Carnazza ML; D'Agata V Neuropeptides; 2010 Feb; 44(1):45-51. PubMed ID: 19919880 [TBL] [Abstract][Full Text] [Related]
19. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. Dodd RD; Mito JK; Eward WC; Chitalia R; Sachdeva M; Ma Y; Barretina J; Dodd L; Kirsch DG Mol Cancer Ther; 2013 Sep; 12(9):1906-17. PubMed ID: 23858101 [TBL] [Abstract][Full Text] [Related]